You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

I am a:
${ profile.name.substring(0, profile.name.length - 1) }
Request Info

Xpert® MRSA NxG

Active MRSA surveillance testing in about an hour

Product Resources MyCepheid Store
Xpert<sup>®</sup> MRSA NxG

The Need

Control of MRSA in healthcare settings requires rapid and accurate tests to detect colonized patients.

  • Approximately 171,200 healthcare-associated MRSA infections are acquired annually in the European Union (EU), resulting in 5,400 attributable deaths, more than 1 million excess days of hospitalization and € 380 million in excess in-hospital costs1
  • Between 2 and 53 million people are estimated to carry MRSA worldwide2
  • The average length of stay (LOS) for all MRSA patients in the EU is 11.5 days with an average attributable cost of €7,478 per patient3

The Solution

Xpert® MRSA NxG is an accurate, fast, on-demand PCR test that will help to:

  • Optimize the effectiveness of your infection control program and guide the judicious use of barrier precautions
  • Guide decolonization practices that reduce infection rates and decrease MRSA transmission
  • Help decrease LOS and improve patient and bed management
  • Help reduce infection control costs by limiting unnecessary use of isolation rooms and improve clinical outcomes
  • Detect the presence of MRSA by targeting both the orfX SCCmec junction and the mecA or mecC genes for a more accurate MRSA detection
  • Improve antibiotic stewardship by avoiding unnecessary

The Impact

Xpert MRSA NxG is an accurate, fast, on-demand PCR test that provides actionable results in about an hour.

Shift your lab from reactive to proactive

  • Rapidly identify MRSA colonized patients that require contact precautions to reduce the risk of transmission and avoid costly outbreaks
  • Improve overall patient safety by reducing the risk of MRSA infection

According to a published German study, implementation of a rapid MRSA screening surveillance program can achieve the following results4

  • Decreased infection rate 50%
  • Reduced cost 58%
  • Total hospital savings € 408,894 in average per year

(1) Köck R, et al. Systematic Literature Analysis and Review of Targeted Preventive Measures to Limit Healthcare-Associated Infections by Meticillin-Resistant Staphylococcus Aureus. Euro Surveill. 2014 Jul 24;19(29):20860.
(2) Grundmann H, et al. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006 Sep 2;368(9538):874-85.
(3) Macedo-Viñas M, et al. Burden of Meticillin-Resistant Staphylococcus Aureus Infections at a Swiss University Hospital: Excess Length of Stay and Costs. J Hosp Infect. 2013 Jun;84(2):132-7.
(4) Walter M, et al. Investment in Rapid on Demand Screening for MRSA and Immediate Isolation of MRSA Positive Patients Reduces Overall Hospital Costs in a German Emergency Hospital. Poster presented at EAHM. 2013 Nov 28-29. Luxembourg.

Ordering Info

Xpert® MRSA NxG

Number of Tests: 120

Catalog #: GXMRSA-NXG-CE-120

Xpert® MRSA NxG

Number of Tests: 10

Catalog #: GXMRSA-NXG-CE-10

Xpert® MRSA NxG

Number of Swabs: 50

Catalog #: 900-0370

Educational Materials

Cost-effectiveness of supplementing a broth-enriched culture test
DOCUMENT

Cost-effectiveness of supplementing a broth-enriched culture test

J. Li, et al. Cost effectiveness of supplementing a broth-enriched culture test with the Xpert MRSA assay for screening inpatients at high risk of MRSA; J Hosp Infect.2012 Dec; 82:227-233

Preemptive Isolation Precautions
DOCUMENT

Preemptive Isolation Precautions

Hallak G, etal. Preemptive Isolation Precautions of Patients at High Risk for Methicillin-Resistant Staphylococcus aureus in Combination With Ultrarapid Polymerase Chain Reaction Screening as an Effective Tool for Infection Control. Infect Control Hosp Epidemiol. 2016 Dec;37(12)1489–1491

Methicillin-resistant Staphylococcus aureus infection rate
DOCUMENT

Methicillin-resistant Staphylococcus aureus infection rate

Stano P et al. Methicillin-resistant Staphylococcus aureus infection rate after implementation of an antibiotic care bundle based on results of rapid molecular screening. In Vivo. 2013 Nov-Dec;27(6):873-876.

AMR
DOCUMENT

AMR

Each time a microorganism becomes resistant to an antibiotic, we lose another weapon in the war against infection. New resistance mechanisms are emerging — and spreading globally — every day. The result? In the very near future, we may be left without any drugs at all to fight serious, resistant infections.1 In the face of diagnostic uncertainty, fast and accurate molecular diagnostics can help provide the information needed. Fight back against antibiotic resistance with diagnostics first. Learn how on-demand molecular testing can help achieve your institution’s Infection Prevention and Antimicrobial Stewardship goals. 1 World Health Organization. “Antimicrobial resistance: global report on surveillance.” June, 2014.

Back to Top